Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of 30 April 2014): 5,349,928,412 Ordinary Shares of 25p each.
- Treasury Shares: 489,174,669 Ordinary Shares.
- Total Voting Rights: 4,860,753,743.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data for previous periods is included in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital and does not contain operational commentary.
Important Facts for Investors to Verify
- Confirm the total number of voting rights (4,860,753,743) to determine notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
- Verify the number of shares held in Treasury (489,174,669) when calculating the denominator for ownership interest calculations.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.